Cyclosporin gel for moderate to severe dry eye
Part of Eyes & vision clinical trials.
This study tests a gel form of cyclosporine for people with moderate to severe dry eye that hasn't improved with other treatments. The gel is applied to the eye to help reduce inflammation and increase tear production.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have had dry eye symptoms in both eyes for at least 6 months.
- Your dry eye discomfort must be rated at least 40 on a 0-to-100 scale.
- You must have a certain level of eye surface damage or staining on exam.
- Your baseline tear production must be 5 mm or less in 5 minutes.
- You cannot have used cyclosporine or similar drugs in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye gel that contains cyclosporine (a medicine that lowers inflammation) to see if it helps with dry eye symptoms. If you have long-lasting dry eye, this study might offer a new treatment option.
This trial tests whether an anti-inflammatory eye drop (ciclosporin A) can help dry eyes by changing immune cells on the eye's surface. It lasts 12 weeks and may be an option for people with moderate to severe dry eye.
This trial tests if using special eye drops (cyclosporine) along with tiny plugs placed in the tear ducts can improve dry eye symptoms in people with Sjögren's syndrome. The goal is to see if this combination works better than the drops alone.
This study compares two different cyclosporine eye drops to see which one better improves the health of the surface of your eye. One is a newer version (Vevye) and the other is a generic version of Restasis, over 8 weeks of treatment.
This trial tests if adding cyclosporine A to the standard natamycin eye drops can better treat fungal eye infections. It may help people with moderate vision loss from a fungal corneal infection.
This study tests a new eye drop (T1695) against cyclosporine for children with moderate to severe vernal keratoconjunctivitis, a type of eye allergy. It aims to see which treatment works better and is safer for reducing symptoms.
Hear when a new Moderate to Severe Dry Eye trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.